Articles about New Research in Multiple Myeloma

Immix Biopharma Inc. shares were up 16% at $2.15 after the company said its Nexcella subsidiary saw positive clinical data from its ongoing Phase 1b/2 study of its B cell maturation antigen-targeted chimeric antigen receptor T cell therapy NXC-201 for the treatment of patients with relapsed or refractory light chain amyloidosis and multiple myeloma.

The company said the data represents eight new evaluable patients in multiple myeloma and three new evaluable patients in light chain amyloidosis.

Nexcella said the overall response rate of 92% produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells showed a median progression-free survival of 12.3 months.

The expected primary endpoint for NXC-201 in relapsed/refractory multiple myeloma is overall response rate and duration of response.

Nexcella said it plans to submit trial results to the Food and Drug Administration for approval once 100 patients are treated with NXC-201.

Immix shares are up 54% in the past 12 months.

Just read this today, thought it might be important
Gina5009